A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/30/2006	WO2006126630A1 Method for preparation of aqueous doripenem solution
11/30/2006	WO2006126625A1 Pharmaceutical comprising pyrazolone derivative
11/30/2006	WO2006126600A1 Pharmaceutical composition for vascular occlusive disease
11/30/2006	WO2006126581A1 Combination drug
11/30/2006	WO2006126541A1 Pharmaceutical composition comprising vitamin k
11/30/2006	WO2006126529A1 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
11/30/2006	WO2006126523A1 Peritoneum protecting agent
11/30/2006	WO2006126514A1 Arylacetate derivative having isoxazole skeleton
11/30/2006	WO2006126505A1 Stat function inhibitor and application thereof
11/30/2006	WO2006126325A1 Agent having antiobesity activity and method of inhibiting obesity
11/30/2006	WO2006126295A1 Preventive and/or therapeutic agent for diabetic vascular disorder and respiratory disorder
11/30/2006	WO2006126171A2 New antibiotic derivatives
11/30/2006	WO2006126083A1 Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
11/30/2006	WO2006126082A2 Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
11/30/2006	WO2006126081A2 Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
11/30/2006	WO2006126034A1 Medicated product for local use based on natural materials
11/30/2006	WO2006125974A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
11/30/2006	WO2006125972A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
11/30/2006	WO2006125958A1 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
11/30/2006	WO2006125930A1 Composition for the treatment of multiple sclerosis
11/30/2006	WO2006125914A2 Use of h11 protein in in vitro diagnosis of streptococcus pyogenes infections
11/30/2006	WO2006125887A1 5h-pyrido[4,3-b]indole derivative compounds and uses thereof as medicine for treating polyglutamin neurodegenerative diseases
11/30/2006	WO2006125812A1 Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament
11/30/2006	WO2006125810A2 Composition for slowing down the development of alzheimer's disease
11/30/2006	WO2006125807A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125805A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125803A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125800A1 17β-HSD1 AND STS INHIBITORS
11/30/2006	WO2006125799A1 Use of glycerol for improving cardiac function
11/30/2006	WO2006125784A1 Tricyclic spiro derivatives as crth2 modulators
11/30/2006	WO2006125778A1 Novel trifluoromethoxy-substituted aryl anilides
11/30/2006	WO2006125774A1 Pediatric formulation of topiramate
11/30/2006	WO2006125665A1 Substituted piperidine antagonist of hi receptor to be used for the treatment of rhinitis
11/30/2006	WO2006125651A2 Ligustilide derivatives for the treatment of inflammatory disorders
11/30/2006	WO2006125642A1 Methods and apparatus for transdermal or transmucosal application of testosterone
11/30/2006	WO2006125622A1 Crystalline form of benzazepinium maleate derivative
11/30/2006	WO2006125621A1 Substituted piperidines as renin inhibitors
11/30/2006	WO2006125616A2 Pyrimidine-based cdk inhibitors for treating pain
11/30/2006	WO2006125596A1 Organic compounds for the treatment of imflammatory or alleric conditions
11/30/2006	WO2006125593A1 Organic compounds
11/30/2006	WO2006125555A2 Quinazolinones
11/30/2006	WO2006125554A1 Use of cyanopyrimidines for the treatment of cardiovascular diseases
11/30/2006	WO2006125548A1 Use of pyrazolopyrimidine against cardiovascular diseases
11/30/2006	WO2006125540A1 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
11/30/2006	WO2006125539A2 Combination therapy comprising diaryl ureas for treating diseases
11/30/2006	WO2006125531A2 Thienopyridines
11/30/2006	WO2006125450A1 Rectal and vaginal suppositories containing misoprostol
11/30/2006	WO2006125397A1 Nonsteroic androgen acceptor regulators, preparation process, pharmaceutical composition and use thereof
11/30/2006	WO2006125324A1 Treatment of protein folding disorders
11/30/2006	WO2006125304A1 Pharmaceutical compositions for treating or preventing coronary artery disease
11/30/2006	WO2006125295A1 Derivatives of 4-or 5-aminosalicylic acid
11/30/2006	WO2006125293A1 Derivatives of 4- or 5-aminosalicylic acid
11/30/2006	WO2006125285A1 Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
11/30/2006	WO2006125276A1 Phenylalkanol compounds
11/30/2006	WO2006125262A1 Methods and compositions for regulating biofilm development
11/30/2006	WO2006113919A3 Aryl alkyl acid derivatives for and use thereof
11/30/2006	WO2006113261A3 Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
11/30/2006	WO2006111858A3 Bis-(coumarin) compounds with anti-inflammatory activity
11/30/2006	WO2006110777B1 Method of treating or preventing bone deterioration or osteoporosis
11/30/2006	WO2006110607A3 Methods for treating infectious disease exacerbated asthma
11/30/2006	WO2006110155A8 Solid forms of linezolid and processes for preparation thereof
11/30/2006	WO2006109323B1 Preparation of [2-methyl-5-phenyl-3-(piperazin-1-ylmethyl)] pyrrole derivatives
11/30/2006	WO2006109075A3 Hydroxybenzamide derivatives and their use as inhibitors of hsp90
11/30/2006	WO2006107902A3 Use of spirostenols to treat mitochondrial disorders
11/30/2006	WO2006104762A3 Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
11/30/2006	WO2006100181A3 New salt and polymorphs of a dpp-iv inhibitor
11/30/2006	WO2006100156A3 Intravascular, interstitial or intraorgan medical access device, and manufacturing method thereof, involving nitric oxide
11/30/2006	WO2006099301A3 Apoptosis inhibitors
11/30/2006	WO2006098979A3 Aminopterin dosage forms and methods for inflammatory disorders
11/30/2006	WO2006098603A3 Composition comprising isoorientin for suppressing histamine
11/30/2006	WO2006096488A3 Composition comprising human igg2 antibody and chelating agent
11/30/2006	WO2006094263A3 Compositions and methods for topical application and transdermal delivery of botulinum toxins
11/30/2006	WO2006092741A3 Treatment of inflammatory disorders with praziquantel
11/30/2006	WO2006088650A3 Method of treating eye injury with local administration of a vegf inhibitor
11/30/2006	WO2006087392A3 Substances, compositions and methods for treating alopecia
11/30/2006	WO2006087206A3 Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (lsd1)
11/30/2006	WO2006086012A8 Antibiotic compound
11/30/2006	WO2006079112A3 Enantioselective synthesis of merrilactone a and its analogs
11/30/2006	WO2006067607A3 Polyacetylen compounds isolated from cussonia
11/30/2006	WO2006066323A9 Formulations and treatments for trichology
11/30/2006	WO2006061715A3 Methylene inhibitors of matrix metalloproteinase
11/30/2006	WO2006055965A3 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
11/30/2006	WO2006055625A3 Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
11/30/2006	WO2006053090A3 Synergistic inhibition of vegf and modulation of the immune response
11/30/2006	WO2006042197A3 Use of del-1 in hair, bone and cartilage regeneration
11/30/2006	WO2006042172A3 Gender differences in experimental aortic aneurysm formation
11/30/2006	WO2006037748A8 Substituted tricyclic benzimidazoles
11/30/2006	WO2006034478A3 Isomigrastatin analogs in the treatment of cancer
11/30/2006	WO2006034207A3 Use of gsk3 inhibitors in combination with radiation therapies
11/30/2006	WO2006023627A8 Rapamycin polymorph ii and uses thereof
11/30/2006	WO2006017409A3 1,3-disubstituted heteroaryl nmda/nr2b antagonists
11/30/2006	WO2006009726A3 Substituted urea derivatives for treating cardiac diseases
11/30/2006	WO2006007095A3 High ibuprofen content granules and their preparation and use
11/30/2006	WO2005113811A3 Combinatorial selection of phosphorothioate aptamers for tgf-beta
11/30/2006	WO2005105147A3 Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases
11/30/2006	WO2005089753A3 Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
11/30/2006	WO2005084636A3 A process for the preparation of controlled-release pharmaceutical composition of metoprolol
11/30/2006	WO2005080384A9 Benzimidazole derivative and use as aii receptor antagonist
11/30/2006	WO2005021707A3 Severe acute respiratory syndrome dna vaccine compositions and methods of use
11/30/2006	WO2004112720A3 Antiviral compositions and methods of using the same

1 ... 3984 3985 3986 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 ... 7860